Epilepsy drug review: patent activity from 1999 to 2002

Bibliography

• HOVINGA CA: Novel anticonvulsant medications in development. Expert Opin. Investig. Drugs (2002) 11:1387–1406.
   PubMed Web of Science ®Google Scholar
• ••Review of novel anticonvulsant compoundsand their possible improvements in clinical outcome.
   Google Scholar
• WOLFE JF, GREENWOOD TD, MULHERON JM: Recent trends in the development of new anti-epileptic drugs. Expert Opin. Ther. Patents (1998) 8:361–381.
   Web of Science ®Google Scholar
• •Summary of existing medications and new compound patent activity from 1993 through 1997.
   Google Scholar
• BRODIE MJ, RICHENS A, YUEN AW: Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet (1995) 345:476–479.
   PubMed Web of Science ®Google Scholar
• MATTSON RH, CRAMER JA, COLLINS IF: A comparison of valproate and carbamazepine for the treatment of complex partial seizures and secondary generalized tonic-clonic seizures in adults. N Engl. J. Med. (1992) 327:765–771.
   PubMed Web of Science ®Google Scholar
• MATTSON RH, CRAMER IA, COLLINS IF: Early tolerance to antiepileptic drug side effects: a controlled trial of 24 patients. In: Tolerance to Beneficial and Adverse Effects of Andepileptic Drugs. Koella WP (Ed), Raven Press, New York, USA (1986):149–156.
   Google Scholar
• SCHMIDT D, GRAM L: Monotherapy versus polytherapy in epilepsy: a reappraisal. CNS Drugs (1995) 3:194–208.
   Web of Science ®Google Scholar
• BRODIE MJ, DICHTER MA: Antiepileptic drugs. N. Eng/. J. Med. (1996) 334:168–175.
   PubMed Web of Science ®Google Scholar
• DECKERS CLP, GENTON P, SILLS GI, SCHMIDT D: Current limitations of antiepileptic drug therapy: a conference review. Epilepsy Res. (2003) 53:1–17.
   PubMed Web of Science ®Google Scholar
• DUNCAN JS: The promise of new antiepileptic drugs. Br. j Clin. Pharmacol. (2002) 53:123–131.
   PubMed Web of Science ®Google Scholar
• BIALER M, JOHANNESSEN SI, KUPFERBERG HI et al.: Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res. (1999) 34:1–41.
   PubMed Web of Science ®Google Scholar
• BIALER M, JOHANNESSEN SI, KUPFERBERG HI et al.: Progress report on new antiepileptic drugs: a summary of the fifth Eilat conference (EILAT V). Epilepsy Res. (2001) 42:11–58.
   Google Scholar
• BIALER M, JOHANNESSEN SI, KUPFERBERG HI et al.: Progress report on new antiepileptic drugs: a summary of the sixth Eilat conference (EILAT VI). Epilepsy Res. (2002) 51:31–71.
   PubMed Web of Science ®Google Scholar
• ••Sunurtary of EILAT conference describingcompounds in clinical development.
   Google Scholar
• RHO JM, SANKAR R: The pharmacologic basis of antiepileptic drug action. Ept/epsia (1999) 40:1471–1483.
   PubMed Web of Science ®Google Scholar
• WONG ICD, LHATOO SD: Adverse reactions to new anticonvulsant drugs. Drug Sal (2000) 23:53–56.
   Web of Science ®Google Scholar
• BRODIE ME CHADWICK DW, HENNING A et al.: Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia (2002) 43:993–1000.
   PubMed Web of Science ®Google Scholar
• BEN-MENACHEM E, PASCAL E, VAN VLEYMEN B et al: Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy Res. (2003) 53:57–64.
   PubMed Web of Science ®Google Scholar
• KLITGAARD H: AED discovery at UCB Pharma: identification of UCB 34714 by novel molecular targets and chronic models of epilepsy. Antiepileptk Drug Congress (Via Key Biscayne, FL, USA (March 20–23 2003).
   Google Scholar
• WESNES KA: The use of cognitive tests to facilitate drug and dose selection in Phase I and to optimise dosing in phase IV. mt. Congress Series (2001) 1220:35–50.
   Google Scholar
• TAYLOR CP, NARASIMHAN LS: Sodium channels and therapy of central nervous system diseases. Adv. Pharmacol (1997) 39:47–98.
   PubMedGoogle Scholar
• CHOI H, MORRELL MJ: Review of lamotrigine and its clinical applications in epilepsy. Expert Opin. Pharmacotherapy (2003) 4:243–251.
   PubMed Web of Science ®Google Scholar
• BROWN GB: 3H-batrachotoxinin-A benzoate binding to voltage-sensitive sodium channels: inhibition by the channel blockers tetrodotoxin and saxitoxin.J. Neurosci. (1986) 6:2064–2070.
   Google Scholar
• FLETCHER CE LUTZ CM, O'SULLIVAN TN et al.: Absence epilepsy in tottering mutant mice is associated with calcium channel defects. Cell (1996) 87:607–617.
   Google Scholar
• FLETCHER CE FRANKEL WN: Ataxic mouse mutants and molecular mechanisms of absence epilepsy. Hum. Mol Genet. (1999) 8:1907–1912.
   PubMed Web of Science ®Google Scholar
• JOUVENCEAU A, EUNSON LH, SPAUSCHUS A et al.: Human epilepsy associated with dysfunction of the brain P/Q-type calcium channel. Lancet (2001) 358:801–807.
   PubMed Web of Science ®Google Scholar
• WHITE HS, PATEL S, MELDRUM BS: Anticonvulsant profile of MDL 27,266: an orally-active, broad-spectrum anticonvulsant agent. Epilepsy Res. (1992) 12:217–226.
   PubMed Web of Science ®Google Scholar
• WHITE HS, WOODHEAD JH, FRANKLIN MR, SWINYARD EA, WOLF HH: Experimental selection, quantification, and evaluation of antiepileptic drugs. In: Andepileptic Drugs (4th edn), Raven Press, New York, USA (1995):99–110.
   Google Scholar
• COULTER DA, HUGUENARD JR, PRINCE DA: Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann. Neurol (1989) 25:582–593.
   PubMed Web of Science ®Google Scholar
• HUGUENARD JR: Neuronal circuitry ofthalamocortical epilepsy and mechanisms of antiabsence drug action. Adv. Neurol (1999) 79:991–999.
   PubMedGoogle Scholar
• WICKENDEN AD: Potassium channels asanti-epileptic drug targets. Neuropharmacology(2002) 43:1055–1060.
   PubMed Web of Science ®Google Scholar
• SINGH NA, CHARLIER C, STAUFFER D et al.: A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat. Genet. (1998) 18:25–29.
   PubMed Web of Science ®Google Scholar
• BIERVERT C, SCHROEDER BC, KUBISCH C et al: A potassium channel mutation in neonatal human epilepsy. (1998) Science. 279: 403–406.
   Google Scholar
• RUNDFELDT C, NETZER R: The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary cells transfected with human KCNQ2/3 subunits. (2000) Neurosci. Lett. 282: 73–76.
   Google Scholar
• WANG HS, PAN Z, SHI W et al: KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science (1998) 282: 1890-1893.
   Google Scholar
• FATOPE MO: Soretolide. Curt Opin. Invest. Drugs (2001) 2:824–827.
   Google Scholar
• SCHRODER RL, JESPERSEN T, CHRISTOPHERSEN P, STROBAEK D, JENSEN BS, OLESEN SP: KCNQ4 channel activation by BMS-204352 and retigabine. Neuropharmacology (2001) 40:888–898.
   PubMed Web of Science ®Google Scholar
• GRIBKOFF VK, STARRETT JE Jr, DWORETZKY SI et al.: Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nat. Med. (2001) 7:471–477.
   PubMed Web of Science ®Google Scholar
• OLSEN RW, MASSIMO A: GABA and epileptogenisis. Ept/epsia (1997) 38:399–407.
   PubMed Web of Science ®Google Scholar
• BOHME I, LUDDENS H. The inhibitory neural circuity as target of antiepileptic drugs. Curt Med. Chem. (2001) 8:1257–1274.
   PubMed Web of Science ®Google Scholar
• HEVERS W, LUDDENS H: The diversity of GABAA receptors. Nol Neurobiol (1998) 18:35–86.
   Google Scholar
• SIEGHART W, SPERK G: Subunit composition, distribution and function of GABAA receptor subtypes. Curt Top. Med. Chem. (2002) 2:795–816.
   PubMedGoogle Scholar
• BERNASCONI R, LAUBER J, MARESCAUX et al.: Experimental absence seizures: potential role of y-hydroxybutyric acid and GABAB receptors Neural Transm. (1992) 35(Suppl.):155–177.
   Google Scholar
• RUDOLPH U, CRESTANI F, MOHLER H: GABAA receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol Set (2001) 22:188–194.
   PubMed Web of Science ®Google Scholar
• HAMILTON NM: Interaction of steroids with the GABAA receptor. Curt Top. Med. Chem. (2002) 2:887–902.
   PubMedGoogle Scholar
• LAN NC, CHEN J-S, JOHNSON D, GEE KW: Differential effects of 4'-chlordiazepam on expressed human GABAA receptors. I Neurochem. (1995) 64:684–688.
   PubMed Web of Science ®Google Scholar
• LAXER K, BLUM D, ABOU-KHALIL BW et al.: Assessment of ganaxolone's anticonvulsant activity using a randomized double-blind presurgical trial design. Epilepsia (2000) 41:1187–1194.
   PubMed Web of Science ®Google Scholar
• BECKER CM: Convulsants acting at the inhibitory glycine receptor. In: Handbook of Experimental Pharmacology Selective Neurotoxicio, (Vol. 104. Herken H, Nucho F (Ed.), Springer Verlag, Berlin, Heidelberg, Germany (1992) 539–575.
   Google Scholar
• ROBA J, CAVALIER R, CORDI A et al: Milacemide. Curt Pro& Epilepsy (1986) 4:179–190.
   Google Scholar
• SUSSAN S, DAGAN A, BLOTNIK S, BIALER M: The structural requirements for the design of antiepileptic-glycine derivatives. Epilepsy Res. (1999) 34:207–210.
   PubMed Web of Science ®Google Scholar
• SUSSAN S, DAGAN A, BIALER M: Pharmacokinetic analysis and anticonvulsant activity of glycine and glycinamide derivatives. Epilepsy Res. (1998) 33:11–21.
   Web of Science ®Google Scholar
• MELDRUM BS, AKBAR MT, CHAPMAN AG: Glutamate receptors and transporters in genetic and acquired models of epilepsy. Epilepsy Res. (1999) 36:189–204.
   PubMed Web of Science ®Google Scholar
• KOHL BK, DANNHARDT G: The NMDA receptor complex: a promising target for novel antiepileptic strategies. Curt Med. Chem. (2001) 8:1275–1289.
   PubMed Web of Science ®Google Scholar
• GILL R, KEMP JA, RICHARDS JG, KEW JNC: NMDA receptor antagonists: past disappointments and future prospects as neuroprotective agents. Curt Opin. Cardiovascular, Pulmonary & Renal Invest. Drugs (1999) 1:576–591.
   Google Scholar
• KEMP JA, MCKERNAN RM: NMDA receptor pathways as drug targets. Nature Neurosci. (2002) 5 (Suppl.) :1039–1042.
   Google Scholar
• DANYSZ W, PARSONS CG, JIRGENSONS A et al.: Amino-alkyl-cyclohexanes as a novel class of uncompetitive NMDA receptor antagonists. Curt Pharmaceutical Design (2002) 8:835–843.
   PubMed Web of Science ®Google Scholar
• MADSEN U, STENSBOL TB, KROGSGARRD-LARSEN P: Inhibitors of AMPA and kainate receptors. Curt Med. Chem. (2001) 8:1292–1301.
   Web of Science ®Google Scholar
• DESOS P, LEPAGNOL JM, MORAIN P et al.: Structure-activity relationships in a series of 2(1H)-quinolones bearing different acidic function in the 3-position: 6,7-dichloro-2(1H)-oxoquinoline-3-phosphonic acid, a new potent and selective AMPA/ kainate antagonist with neuroprotective properties. .1. Med. Chem (1996) 39:197–206.
   Google Scholar
• TARNAWA I, FARKAS S, BERZSENYI P et al.: Elecrophysiological studies with a 2,3-benzodiazepine muscle relaxant: GYKI 52466. Eur.j PharmacoL (1989) 167:193–199.
   PubMed Web of Science ®Google Scholar
• ROUTLEDGE C, BROMIDGE SM, MOSS SF et al.: Characterization of SB-271046: a potent, selective and orally active 5-HT6 receptor antagonist. Br. Pharmacol (2000) 130:1606–1612.
   PubMed Web of Science ®Google Scholar
• STEAN TO, WARREN DH, THOMAS DR et al.: Pharmacological profile of SB-357134: a potent, selective, brain penetrant, and orally-active 5-HT6 receptor antagonist. Pharmacol Biochem. Behav (2002) 71:645–654.
   PubMed Web of Science ®Google Scholar
• DAWSON LA, NGUYEN HQ, LIP: In vivo effects of the 5-HT6 antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate. Br. Pharmacol (2000) 130:23–26.
   PubMed Web of Science ®Google Scholar
• BROMIDGE SM, CLARKE SE, GAGER T et al.: Phenyl benzenesulfonamides are novel and selective 5-HT6 antagonists: identification of N-(2,5-dibromo-3-fluoropheny1)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide (SB-357134). Bioorganic Med. Chem. Lett. (2001) 11:55–58.
   PubMed Web of Science ®Google Scholar
• SCHOEPP DD: Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. Pharmacol Exp. Ther. (2001) 299:12–20.
   PubMed Web of Science ®Google Scholar
• BRUNO V, BATTAGLIA G, COPANI A et al.: Metabotropic glutamate receptor subsubtypes as targets for neuroprotective drugs. Cereb. Blood Flow Metab. (2001) 21:1013–1033.
   PubMed Web of Science ®Google Scholar
• DOHERTY J, DINGLEDINE R: The roles of metabotroic glutamate receptors in seizures and epilepsy. Can: Drug Targets-CNS & Neurol Disorders (2002) 1:251–260.
   PubMed Web of Science ®Google Scholar
• CHAN WN, EVANS JM, HADLEY MS et al.: Synthesis of novel trans-4-(substituted-benzamido)-3,4-dihydro-2H- benzo[b]-pyran-3-ol derivatives as potential anticonvulsant agents with a distinctive binding profile. j. Med. Chem. (1996) 39:4537–4539.
   PubMed Web of Science ®Google Scholar
• CAESER M, EVANS ML, BENHAM CD: Lack of effect of the novel anticonvulsant SB-204269 on voltage-dependent currents in neurones cultured from rat hippocampus. Neurosci. Lett. (1999) 271:57–60.
   PubMed Web of Science ®Google Scholar
• CHOI D, STABLES JP, KOHN H: Synthesis and anticonvulsant activities of N-benzy1-2-acetamidopropionamide derivatives.j Med. Chem. (1996) 39:1907–1916.
   PubMed Web of Science ®Google Scholar
• EDAFIOGHO 10, ALEXANDER MS, MOOR JA et al.: Anticonvulsant enaminones: with emphasis on methyl 4- [(p-chlorophenyl) amino] -6-methy1-2-oxocyclohex 3 en 1 oate (ADD 196022). Current Med. Chem. (1994) 1:159–175.
   Google Scholar
• RAASCH W, SCHAFER U, CHUN J, DOMINIAK P: Biological significance of agmatine, an endogenous ligand at imidazoline binding sites. Br. Pharmacol (2001) 133:755–780.
   PubMed Web of Science ®Google Scholar
• WHITE HS, WOODBURY DM, CHEN CE KEMP JW, CHOW SY, YEN-CHOW YC: Role of glial cation and anion transport mechanisms in etiology and arrest of seizures. Adv. Neurol (1986) 44:695–712.
   PubMedGoogle Scholar
• GUILLAUME D, GRISAR T, VERGNIOLLE-BURETTE M: Glial contribution to seizure: carbonic anhydrase activity in epileptic mammalian brain. Epilepsia (1991) 32:10–15.
   PubMed Web of Science ®Google Scholar
• PITTLER MH, ERNST E: Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. j. Clin. Psychopharmacol (2000) 20:84–89.
   PubMed Web of Science ®Google Scholar
• BACKHAUSS C, KRIEGLSTEIN J: Extract of kava (Piper methysticum) and methysticin constituents protect brain tissue against ischemic damage in rodents. Eur. Pharmacol (1992) 215:265–269.
   PubMed Web of Science ®Google Scholar
• GRUNZE H, LANGOSCH J, SCHIRRMACHER K, BINGMANN D, VON WEGERER J, WALDEN J: Kava pyrones exert effects on neuronal transmission and transmembraneous cation currents similar to established mood stabilizers-a review. Progressin Neuro-Psychopharmacology & Biol. Psychiatry(2001) 25:1555–1570.
   PubMed Web of Science ®Google Scholar
• RHO JM, ANDERSON GD, DONEVAN SD, WHITE HS: Acetoacetate, acetone, and dibenzylamine (a contaminant in 1- (+)-I3-hydroxybutyrate) exhibit direct anticonvulsant actions in vivo. Epilepsia. (2002) 43:358–361.
   PubMed Web of Science ®Google Scholar
• PERUCCA E. Marketed new antiepileptic drugs: are they better than old-generation agents? Ther. Drug Monitoring(2002) 24:74–80.
   PubMed Web of Science ®Google Scholar